ex vivo-expanded autologous T cells IMA101

A preparation of autologous cytotoxic T lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T cells IMA101 target and kill tumor cells. The T cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.